ClinicalTrials.Veeva

Menu

Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRI

Fudan University logo

Fudan University

Status

Enrolling

Conditions

Breast Cancer

Treatments

Other: Response monitoring

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The study will assess whether changes in kinetic parameters of tumor and peritumoral vasculature using ultrafast dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with breast cancer appropriate for NAC. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.

Enrollment

80 estimated patients

Sex

Female

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Female;

  2. Age 18 years or older;

  3. Diagnosis of invasive breast cancer by ultrasound guided biopsy;

  4. Planed for receiving neoadjuvant chemotherapy (NAC) 4. Planned definitive breast surgery following completion of NAC.

Exclusion criteria

  1. Stage IV breast cancer;
  2. Previous ipsilateral breast cancer;
  3. Previous treatment (chemotherapy or radiation) to involved breast;
  4. Medically unstable;
  5. Pregnant or nursing.

Trial contacts and locations

1

Loading...

Central trial contact

Yajia Gu, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems